PFAS linkage
- Some occupational and environmental studies have explored associations between PFAS exposure and prostate cancer risk, including in firefighting and industrial settings.
- PFAS may affect hormonal, immune, inflammatory, and metabolic pathways relevant to cancer development, though evidence can vary by compound and population.
- Because prostate cancer has many risk factors, detailed exposure documentation is especially important for intake review.
Prostate cancer symptoms
- Frequent urination, especially at night
- Difficulty starting urination or weak urine flow
- Blood in urine or semen
- Pain in the pelvis, hips, back, or bones in advanced cases
- Unexplained weight loss, fatigue, or urinary retention in some cases
Diagnosis and medical records
- PSA blood testing and digital rectal examination
- Prostate MRI or other imaging for suspicious findings
- Prostate biopsy with Gleason grade group and pathology review
- Bone scan, CT, PET, or other staging tests for high-risk or advanced disease
Treatment options
- Active surveillance for selected low-risk prostate cancer
- Radical prostatectomy or radiation therapy for localized disease
- Hormone therapy, chemotherapy, immunotherapy, or targeted therapy for advanced disease
- Palliative radiation or procedures for bone pain or urinary obstruction when needed
What patients should gather for intake
- Gather PSA history, biopsy reports, Gleason score, staging scans, and treatment summaries.
- Note any firefighting, military, airport, industrial, or contaminated-water exposure history.
- Include whether the cancer was metastatic, recurrent, high-grade, or required systemic therapy.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to qualified national PFAS co-counsel.